All Stories

  1. Synthesis of sulfated alginate from its tributylammonium salt: Comparing the sulfating agents H2SO4-DCC and SO3·py
  2. Identification of a Pentasaccharide Lead Compound with High Affinity to the SARS-CoV-2 Spike Protein via In Silico Screening
  3. C-5 Epimerisation of D-Mannopyranosyl Fluorides: The Influence of Anomeric Configuration on Radical Reactivity
  4. A prohibitin-targeting drug modifies aspects of disease in a mouse model of Sanfilippo syndrome
  5. Synthesis of Uronic Acid 1‐Azasugars as Putative Inhibitors of α‐Iduronidase, β‐Glucuronidase and Heparanase**
  6. Siderophore conjugates to combat antibiotic-resistant bacteria
  7. An Enzymatic Activity Assay for Heparanase That Is Useful for Evaluating Clinically Relevant Inhibitors and Studying Kinetics
  8. Synthesis of a Gal-β-(1→4)-Gal disaccharide as a ligand for the fimbrial adhesin UcaD
  9. Evidence for Multiple Binding Modes in the Initial Contact Between SARS‐CoV‐2 Spike S1 Protein and Cell Surface Glycans**
  10. An Improved Protocol for the Stereoselective Synthesis of β-d-Glycosyl Fluorides from 2-O-Acyl Thioglycosides
  11. Initial contact between SARS-CoV-2 spike S1 protein and cell surface glycans involves multiple binding modes
  12. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 by Disrupting the Spike–ACE2 Interaction
  13. Au‐NHC complexes with thiocarboxylate ligands: Synthesis, structure, stability, thiol exchange and in vitro anticancer activity
  14. Tumour cell-activated platelets modulate the immunological activity of CD4+, CD8+, and NK cells, which is efficiently antagonized by heparin
  15. Structural Insights into Pixatimod (PG545) Inhibition of Heparanase, a Key Enzyme in Cancer and Viral Infections
  16. SARS-CoV-2 Triggers Complement Activation through Interactions with Heparan Sulfate
  17. SARS‐CoV‐2 triggers complement activation through interactions with heparan sulfate
  18. Development of Improved Synthetic Routes to Pixatimod (PG545), a Sulfated Oligosaccharide-Steroid Conjugate
  19. From Cancer to COVID‐19: A Perspective on Targeting Heparan Sulfate‐Protein Interactions
  20. Corrigendum: Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo
  21. A Substituent‐Directed Strategy for the Selective Synthesis of L‐Hexoses: An Expeditious Route to L‐Idose
  22. Inhibition of Tumor–Host Cell Interactions Using Synthetic Heparin Mimetics
  23. Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain
  24. Heparin Inhibits Cellular Invasion by SARS-CoV-2: Structural Dependence of the Interaction of the Spike S1 Receptor-Binding Domain with Heparin
  25. GlycoTorch Vina: Docking Designed and Tested for Glycosaminoglycans
  26. Heparanase Promotes Syndecan-1 Expression to Mediate Fibrillar Collagen and Mammographic Density in Human Breast Tissue Cultured ex vivo
  27. Sulfonated RAFT Copolymers as Heparin Mimetics: Synthesis, Reactivity Ratios, and Anticoagulant Activity
  28. A Fluorogenic Heparan Sulfate Disaccharide for the Measurement of Heparanase Activity
  29. Synthetic Heparan Sulfate Mimetic Pixatimod (PG545) Potently Inhibits SARS-CoV-2 By Disrupting The Spike-ACE2 interaction
  30. Heparanase promotes Syndecan-1 expression to mediate fibrillar collagen and mammographic density in human breast tissue cultured ex vivo
  31. GlycoTorch Vina: Improved Docking of Sulfated Sugars Using QM-derived Scoring Functions
  32. PI-88 and Related Heparan Sulfate Mimetics
  33. Mucopolysaccharidosis type II (Hunter syndrome): Clinical and biochemical aspects of the disease and approaches to its diagnosis and treatment
  34. Structural insights into heparanase activity using a fluorogenic heparan sulfate disaccharide
  35. Anticoagulant Heparin Mimetics via RAFT Polymerization
  36. Synthetic Disaccharide Standards Enable Quantitative Analysis of Stored Heparan Sulfate in MPS IIIA Murine Brain Regions
  37. PG545 treatment reduces RRV-induced elevations of AST, ALT with secondary lymphoid organ alterations in C57BL/6 mice
  38. Dual targeting of dengue virus virions and NS1 protein with the heparan sulfate mimic PG545
  39. In Vitro Enzymatic Digestibility of Glutaraldehyde-Crosslinked Chitosan Nanoparticles in Lysozyme Solution and Their Applicability in Pulmonary Drug Delivery
  40. Cross-Species Analysis of Glycosaminoglycan Binding Proteins Reveals Some Animal Models Are “More Equal” than Others
  41. The Development of Assays for Heparanase Enzymatic Activity: Towards a Gold Standard
  42. Applications of Ion Mobility-Mass Spectrometry in Carbohydrate Chemistry and Glycobiology
  43. Structural and conformational studies of the heparan sulfate mimetic PI-88
  44. Glycosylations of Simple Acceptors with 2-O -Acyl l -Idose or l -Iduronic Acid Donors Reveal Only a Minor Role for Neighbouring-Group Participation
  45. Heparin mimetics with anticoagulant activity
  46. Prophylactic Antiheparanase Activity by PG545 Is Antiviral In Vitro and Protects against Ross River Virus Disease in Mice
  47. Synthesis and mass spectrometric analysis of disaccharides from methanolysis of heparan sulfate
  48. New structural insights into the oligosaccharide phosphate fraction of Pichia ( Hansenula ) holstii NRRL Y2448 phosphomannan
  49. Carbohydrate– N -heterocyclic carbene metal complexes: Synthesis, catalysis and biological studies
  50. Glycosaminoglycans and Their Mimetics
  51. Effects of Chemical Conjugation of l-Leucine to Chitosan on Dispersibility and Controlled Release of Drug from a Nanoparticulate Dry Powder Inhaler Formulation
  52. Recent advances in chitosan-based nanoparticulate pulmonary drug delivery
  53. Synthesis of Mannose-Cholesterol Conjugates for Targeted Liposomal Drug Delivery
  54. The Tortoise and the Hare: Evolving Regulatory Landscapes for Biosimilars
  55. The stereoselectivities of tributyltin hydride-mediated reductions of 5-bromo-d-glucuronides tol-iduronides are dependent on the anomeric substituent: syntheses and DFT calculations
  56. Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk
  57. Investigations into the decomposition of aminoacyl-substituted monosaccharide scaffolds from a drug discovery library
  58. Synthetic Approaches to l-Iduronic Acid and l-Idose
  59. Synthesis and Toxicological Evaluation of a Chitosan- l -Leucine Conjugate for Pulmonary Drug Delivery Applications
  60. ChemInform Abstract: Attempted Synthesis of the Imidazylate (III) of an α-Hydroxylactone (I) Results in Unexpected Chlorination: Synthesis and X-Ray Crystal Structure of 5-Chloro-5-deoxy-1,2-O-isopropylidene-β-L-idurono-6,3-lactone (II).
  61. Attempted Synthesis of the Imidazylate of an α-Hydroxylactone Results in Unexpected Chlorination: Synthesis and X-Ray Crystal Structure of 5-Chloro-5-deoxy-1,2-O-isopropylidene-β-l-idurono-6,3-lactone
  62. Low-molecular-weight heparin biosimilars: potential implications for clinical practice
  63. 1H NMR spectroscopic studies establish that heparanase is a retaining glycosidase
  64. Structure and stereochemistry of an anti-inflammatory anhydrosugar from the Australian marine sponge Plakinastrella clathrata and the synthesis of two analogues
  65. Heparan sulfate inhibitors and their therapeutic implications in inflammatory illnesses
  66. ChemInform Abstract: A Focused Sulfated Glycoconjugate Ugi Library for Probing Heparan Sulfate-Binding Angiogenic Growth Factors.
  67. MicroRNAs Regulate Tumor Angiogenesis Modulated by Endothelial Progenitor Cells
  68. A focused sulfated glycoconjugate Ugi library for probing heparan sulfate-binding angiogenic growth factors
  69. Synthesis of Disaccharides Containing 6-Deoxy-a-L-talose as Potential Heparan Sulfate Mimetics
  70. Synthesis of a Heparan Sulfate Mimetic Library Targeting FGF and VEGF via Click Chemistry on a Monosaccharide Template
  71. Discovery of PG545: A Highly Potent and Simultaneous Inhibitor of Angiogenesis, Tumor Growth, and Metastasis
  72. Potent anti-respiratory syncytial virus activity of a cholestanol-sulfated tetrasaccharide conjugate
  73. PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models
  74. Synthesis of simple heparanase substrates
  75. Lipophile-conjugated sulfated oligosaccharides as novel microbicides against HIV-1
  76. A highly lipophilic sulfated tetrasaccharide glycoside related to muparfostat (PI-88) exhibits virucidal activity against herpes simplex virus
  77. Synthesis and Biological Evaluation of Polysulfated Oligosaccharide Glycosides as Inhibitors of Angiogenesis and Tumor Growth
  78. Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening
  79. Synthesis of a heparan sulfate mimetic disaccharide with a conformationally locked residue from a common intermediate
  80. ChemInform Abstract: An Improved Synthetic Route to the Potent Angiogenesis Inhibitor Benzyl Manα(1→3)Manα(1→3)-Manα (1→3)Manα(1→2)-Man Hexadecasulfate.
  81. The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy
  82. An Improved Synthetic Route to the Potent Angiogenesis Inhibitor Benzyl Manα(1→3)-Manα(1→3)-Manα(1→3)-Manα(1→2)-Man Hexadecasulfate
  83. A surface plasmon resonance-based solution affinity assay for heparan sulfate-binding proteins
  84. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88
  85. Design, synthesis, FGF-1 binding, and molecular modeling studies of conformationally flexible heparin mimetic disaccharides
  86. Molecular basis for resistance of herpes simplex virus type 1 mutants to the sulfated oligosaccharide inhibitor PI-88
  87. Herpes Simplex Virus Type 2 Glycoprotein G Is Targeted by the Sulfated Oligo- and Polysaccharide Inhibitors of Virus Attachment to Cells
  88. PI-88 and Novel Heparan Sulfate Mimetics Inhibit Angiogenesis
  89. Enantiospecific synthesis of the heparanase inhibitor (+)-trachyspic acid and stereoisomers from a common precursor
  90. Inhibition of Plasmodium falciparum Growth In Vitro and Adhesion to Chondroitin-4-Sulfate by the Heparan Sulfate Mimetic PI-88 and Other Sulfated Oligosaccharides
  91. Synthesis, Biological Activity, and Preliminary Pharmacokinetic Evaluation of Analogues of a Phosphosulfomannan Angiogenesis Inhibitor (PI-88)
  92. Towards the synthesis of aryl glucuronides as potential heparanase probes. An interesting outcome in the glycosidation of glucuronic acid with 4-hydroxycinnamic acid
  93. The Synthesis and Biological Evaluation of Two Analogues of the C-Riboside Showdomycin.
  94. Use of Sulfated Linked Cyclitols as Heparan Sulfate Mimetics to Probe the Heparin/Heparan Sulfate Binding Specificity of Proteins
  95. The Synthesis and Biological Evaluation of Two Analogues of the C -Riboside Showdomycin
  96. The synthesis of phosphorylated disaccharide components of the extracellular phosphomannan of Pichia (Hansenula) holstii NRRL Y-2448
  97. A Synthetic Heparanase Inhibitor Reduces Proteinuria in Passive Heymann Nephritis
  98. Application of the Four-Component Ugi Condensation for the Preparation of Sulfated Glycoconjugate Libraries.
  99. The Development of Inhibitors of Heparanase, a Key Enzyme Involved in Tumour Metastasis, Angiogenesis and Inflammation
  100. The low molecular weight heparan sulfate-mimetic, PI-88, inhibits cell-to-cell spread of herpes simplex virus
  101. Application of the four-component Ugi condensation for the preparation of sulfated glycoconjugate libraries
  102. Probing the Interactions of Phosphosulfomannans with Angiogenic Growth Factors by Surface Plasmon Resonance
  103. Preparation and anticoagulant activity of the phosphosulfomannan PI-88
  104. PROBING THE INTERACTIONS OF PI-88 WITH ANGIOGENIC GROWTH FACTORS BY SURFACE PLASMON RESONANCE
  105. SULFATED OLIGOSACCHARIDE-BASED INHIBITORS OF TUMOUR GROWTH AND METASTASIS
  106. INHIBITION OF HERPES SIMPLEX VIRUS INFECTION BY PI-88, AN ANTAGONIST OF HEPARAN SULFATE-PROTEIN INTERACTIONS
  107. HEPARAN SULFATE-MIMETICS AS INHIBITORS OF CANCER
  108. Determination of the composition of the oligosaccharide phosphate fraction of Pichia (Hansenula) holstii NRRL Y-2448 phosphomannan by capillary electrophoresis and HPLC
  109. Synthesis of [14C]- and [35S]-labelled PI-88 for pharmacokinetic and tissue distribution studies
  110. Characterisation of the Anticoagulant Properties of a Range of Structurally Diverse Sulfated Oligosaccharides
  111. Large-scale preparation of the oligosaccharide phosphate fraction of Pichia holstii NRRL Y-2448 phosphomannan for use in the manufacture of PI-88
  112. Article
  113. Convergent synthesis of a fluorescence-quenched glycopeptide as a potential substrate for peptide: N-glycosidases
  114. N-Glycosyl phosphonamidates: potential transition-state analogue inhibitors of glycopeptidases
  115. Internally quenched fluorogenic, α-helical dimeric peptides and glycopeptides for the evaluation of the effect of glycosylation on the conformation of peptides
  116. The Synthesis of Some Epoxyalkyl b-C-Glycosides as Potential Inhibitors of b-Glucan Hydrolases
  117. Analysis of the1H NMR spectra of some diethyl phosphonates
  118. Synthesis of 2′- and 2″-O-acylated maltotriosides as potential fluorescence-quenched substrates for α-amylase
  119. Approaches to the Synthesis of Retronecine From Some Pyrrolidine Precursors
  120. The Synthesis of Some Pyrrolidines as Potential Precursors to Retronecine
  121. An Improvement in the Preparation of Some Carbohydrate Benzylidene Acetals